General information about	com	pany	
Scrip code	5399	938	
NSE Symbol	NO	TLISTED	
MSEI Symbol	NOTLISTED		
ISIN	INE858Q01019		
Name of the entity	MEDICO INTERCONTINENTAL LIMITED		
Date of start of financial year	01-04-2024		
Date of end of financial year	31-03-2025		
Reporting Quarter Type	Year	rly	
Date of Quarter Ending	31-0	03-2025	
Type of company	Equ	ity	
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes		
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes		
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No	There were no acquisition of shares or voting rights in unlisted companies during the period under review.	
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	No	There were no imposition of fine or penalty during the period under review.	
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	No	There were no Ongoing Tax Litigations or Disputes during the period under review.	
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	No	There were no Loans / Guarantees / Comfort letters / Securities provided during the period under review.	
Risk management committee	Not	Applicable	
Market Capitalisation as per immediate previous Financial Year	Any	other	
Is SCORE ID Available ?	Yes		
SCORE Registration ID	i004	133	
Reason For No SCORE ID			
Type of Submission	Orig	ginal	
Remarks (website dissemination)			
Remarks for Exchange (not for Website Dissemination)			

				Anne	xure I									
	Annexure I to be submitted by listed entity on quarterly basis													
	I. Composition of Board of Directors													
	Disclosure of notes on composition of board of directors explanatory													
	Whether the listed entity has a Regular Chairperson Yes													
	Whether Chairperson is related to MD or CEO Yes													
Sr	Title (Mr / Ms) Name of the Director PAN DIN Category 1 of directors Category 2 of directors Category 3 of directors													
1	Mr	ANKUR AMIRAM DAVE	AAJPD6657K	01059786	Non-Executive - Independent Director	Not Applicable		07-07- 1972						
2	Mr	SAMIR DILIPKUMAR SHAH	ACWPS4410N	03350268	Executive Director	Not Applicable	MD	18-02- 1978						
3	Mrs	TANVI SAMIRBHAI SHAH	AFQPS3469C	08192047	Non-Executive - Non Independent Director	Chairperson related to Promoter		04-10- 1978						
4	Mrs	SWATI VIKRAMKUMAR SHAH	EEOPS0306R	08420884	Non-Executive - Non Independent Director	Not Applicable		20-10- 1991						
5	Mr	PARSHWA KAUSHAL SHAH	DDDPS1403L	07400081	Non-Executive - Independent Director	Not Applicable		27-12- 1991						
6	PRIVANK I ALITRHAL Non-Executive - 36													

	I. Composition of Board of Directors												
	Disqualification of Directors under section 164 of the Companies Act, 2013												
Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status								
1	No				Active								
2	No				Active								
3	No				Active								
4	No				Active								
5	No				Active								
6	No				Active								

					I. Co	ompositi	on of Board	of Directors					
Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Reappointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	NA		23-03- 2019	23-03- 2024		72.07	1	1	3	3			
2	NA		14-08- 2018	14-08- 2023			1	0	0	0			
3	NA		14-08- 2018				1	0	3	0			
4	NA		29-05- 2019				1	0	0	0			
5	NA		10-05- 2024			10.2	1	1	0	0			
6	NA		14-11- 2022			28.16	1	1	3	0			

Au	Audit Committee Details												
Sr	DIN Number	Date of Appointment	Date of Cessation	Remarks									
1	1 01059786 ANKUR AMIRAM Non-Executive - Independent Director			Chairperson	23-03-2019								
2	09784354	PRIYANK LALITBHAI SANCHETI	Member	14-11-2022									
3	3 108102007 1		Non-Executive - Non Independent Director	Member	14-08-2018								

No	Nomination and remuneration committee												
	Wh	ether the Nomination and re	egular Chairperson	Yes									
Sr	DIN Number	Name of Committee members	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks							
1	01059786 ANKUR AMIRAM Non-Executive - Independent Director			Chairperson	23-03-2019								
2	09784354	PRIYANK LALITBHAI SANCHETI	Member	14-11-2022									
3	08192047	TANVI SAMIRBHAI SHAH	Non-Executive - Non Independent Director	Member	14-08-2018								

Sta	Stakeholders Relationship Committee												
	,	Whether the Stakeholders Re	egular Chairperson	Yes									
Sr	DIN Number	Name of Committee members	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks							
1	01059786 ANKUR AMIRAM Non-Executive - Independent Director		Chairperson	23-03-2019									
2	09784354	PRIYANK LALITBHAI SANCHETI	Member	14-11-2022									
3	08192047	TANVI SAMIRBHAI SHAH	Non-Executive - Non Independent Director	Member	14-08-2018								

Ris	Risk Management Committee											
		Whether the Risk Manage			·							
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks					

Co	Corporate Social Responsibility Committee												
	Whether the	e Corporate Social Responsil	oility Committee has a	Regular Chairperson									
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks						

•	Other Commit	ee				
5	r DIN Numbe	r Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

				Anı	nexure 1						
Annexure 1											
III. N	Meeting of Boa	ard of Directo	ors								
	sclosure of note oard of director										
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*			
1	14-11-2024				Yes	6	5	3			
2		14-02-2025	91		Yes	6	6	3			

	Annexure 1											
IV.	V. Meeting of Committees											
		Disclos	sure of notes o	n meeting of	f committee	s explanatory						
Sr	Sr Name of Committee of Previous quarter and consecutive consecutive committee of Previous quarter and consecutive committee of Quorup met					Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)		
1	Audit Committee	14-11-2024				Yes	3	3	2	0		
2	Audit Committee	14-02-2025	91			Yes	3	3	2	0		
3	Stakeholders Relationship Committee	14-02-2025				Yes	3	3	2	0		

	Annexure 1				
V	Affirmations				
Sr	Subject	Compliance status (Yes/No)			
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes			
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes			
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes			
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes			
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	NA			
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes			
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes			
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes			

	Annexure 1		
Sr	Subject	Compliance status	
1	Name of signatory	PUNEETA SHARMA	
2	Designation	Company Secretary and Compliance Officer	

## Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year) I. Disclosure on website in terms of LODR Regulation Sr If status is "No" Compliance details of Sr Item status Web address non-(Yes/No/NA) compliance may be given here. As per regulation 46(2) of the LODR: Details of 1.1 Yes https://medicointercontinental.com/about/ business Memorandum of Association 1.2 Yes https://medicointercontinental.com/investors/moa-aoa/ and Articles of Association Brief profile of board of directors including 1.3 directorship Yes https://medicointercontinental.com/about/ and full-time positions in body corporates Terms and conditions of appointment 2 Yes https://medicointercontinental.com/wp-content/uploads/2019/06/ID-Policy.pdf independent directors Composition of various 3 committees of Yes https://medicointercontinental.com/directors/ board of directors Code of conduct of board of directors and Yes https://medicointercontinental.com/wp-content/uploads/2023/05/Code of Conduct N-1.pdf senior management personnel Details of establishment of vigil https://medicointercontinental.com/wp-content/uploads/2019/06/MIL-Whistle-Blower-Policy.pdf Yes mechanism/ Whistle Blower policy Criteria of making https://medicointercontinental.com/wp-content/uploads/2024/04/criteria-for-making-payments-to-6 payments to Yes non-executive-directors\_N.pdf non-executive directors Policy on https://medicointercontinental.com/wpdealing with Yes related party content/uploads/2023/05/Policy Related Party Transaction N.pdf transactions Policy for determining 8 Yes https://medicointercontinental.com/wp-content/uploads/2024/04/Material\_Subsidiary\_Policy\_N.pdf 'material' subsidiaries Details of familiarization https://medicointercontinental.com/wpprogrammes Yes $content/uploads/2023/05/Policy\_on\_Familiarisation\_Programme\_for\_Independent\_Directors\_N.pdf$ imparted to independent

directors

10	Email address for grievance redressal and other relevant details	Yes	https://medicointercontinental.com/investors/investor-grievance/
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes	https://medicointercontinental.com/investors/investor-grievance/
12	Financial results	Yes	https://medicointercontinental.com/investors/financials/
13	Shareholding pattern	Yes	https://medicointercontinental.com/investors/shareholding-pattern/
14	Details of agreements entered into with the media companies and/or their associates	NA	

All	Annexure II to be submitted by listed entity at the end of the financial year (for the whole of financial year)						
~	I. Disclosure on website in terms of LODR Regulation						
Sr		I I	T				
	As per regulation 46(2) of the LODR:						
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	NA					
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	NA					
16	New name and the old name of the listed entity	NA					
17	Advertisements as per regulation 47 (1)	Yes	https://medicointercontinental.com/investors/newspaper-publication/				
18	Credit rating or revision in credit rating obtained	NA					
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	Yes	https://medicointercontinental.com/investors/financials-of-subsidiaries/				
20	Secretarial Compliance Report	Yes	https://medicointercontinental.com/investors/secretarial-compliance-report/				
21	Materiality Policy as per Regulation 30 (4)	Yes	https://medicointercontinental.com/wp-content/uploads/2023/03/Policy-on-Materiality-mIL.pdf				
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes	https://medicointercontinental.com/wp-content/uploads/2023/05/Contact_details_of_KMP_to_determine_materiality_N.pdf				
23	Disclosures under regulation 30(8)	Yes	https://medicointercontinental.com/investors/policies/				
24	Statements of deviation(s) or variations(s) as specified in regulation 32	NA					
25	Dividend Distribution policy as per Regulation 43A(1)	NA					
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes	https://medicointercontinental.com/investors/annual-return/				
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	NA					
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes	https://medicointercontinental.com/investors/				
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes	https://medicointercontinental.com/				

		Annexure II		
II.	Annual Affirmations			
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

	Annexure II				
II.	Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.	
11	Risk Assessment & Management	17(9)	Yes		
12	Performance Evaluation of Independent Directors	17(10)	Yes		
13	Recommendation of Board	17(11)	Yes		
14	Maximum number of Directorships	17A	Yes		
15	Composition of Audit Committee	18(1)	Yes		
16	Meeting of Audit Committee	18(2)	Yes		
17	Role of Audit Committee and information to be reviewed by the audit committee	18(3)	Yes		
18	Composition of nomination & remuneration committee	19(1) & (2)	Yes		
19	Quorum of Nomination and Remuneration Committee meeting	19(2A)	Yes		
20	Meeting of Nomination and Remuneration Committee	19(3A)	Yes		

	Annexure II				
II.	Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	
21	Role of Nomination and Remuneration Committee	19(4)	Yes		
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes		
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes		
24	Role of Stakeholders Relationship Committee	20(4)	Yes		
25	Composition and role of risk management committee	21(1),(2),(3),(4)	NA		
26	Meeting of Risk Management Committee	21(3A)	NA		
27	Quorum of Risk Management Committee meeting	21(3B)	NA		
28	Gap between the meetings of the Risk Management Committee	21(3C)	NA		
29	Vigil Mechanism	22	Yes		
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes		

	Annexure II				
II.	Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes		
32	Approval for material related party transactions	23(4)	Yes		
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes		
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	Yes		
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3),(4), (5) & (6)	Yes		
36	Alternate Director to Independent Director	25(1)	NA		
37	Maximum Tenure	25(2)	Yes		
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes		
39	Meeting of independent directors	25(3) & (4)	Yes		
40	Familiarization of independent directors	25(7)	Yes		

	Annexure II				
II.	Annual Affirmations				
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	
41	Declaration from Independent Director	25(8) & (9)	Yes		
42	Directors and Officers insurance	25(10)	NA		
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	NA		
44	Memberships in Committees	26(1)	Yes		
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes		
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes		
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	NA		
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	NA		
	Any other information to be provided - Add Notes				

Annexure II		
1	Name of signatory	PUNEETA SHARMA
2	Designation	Company Secretary and Compliance Officer

	Annexure II				
III. Affirmations					
Sr	Particulars	Compliance status (Yes/No/NA)			
1	The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	Yes			
	Any other information to be provided				

Annexure II		
1	Name of signatory	PUNEETA SHARMA
2	2 Designation	Company Secretary and Compliance Officer

Details of Cyber security incidence					
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter					
Number of cyber security incidence or breaches or loss of data event occurred during the quarter					
Sr.	Date of the event	Brief details of the event			

Signatory Details					
Name of signatory	PUNEETA SHARMA				
Designation of person	Company Secretary and Compliance Officer				
Place	AHMEDABAD				
Date	14-04-2025				

Investor Grievance Details				
No. of investor complaints pending at the beginning of Quarter	0			
No. of investor complaints received during the Quarter	0			
No. of investor complaints disposed off during the Quarter				
No. of investor complaints those remaining unresolved at the end of the Quarter	0			